Contactless wireless health monitoring system shows potential for use in clinical trials
Cambridge, MA, May 23, 2019 – Over the past year Novartis, in collaboration with the MIT Center for Wireless Networks and Mobile Computing, has tested a novel technology for passive, contactless monitoring of physiological signals that may be used to monitor clinical trial patients in their homes. Developed by Professor Dina Katabi and her students, the technology consists of a Wi-Fi-like device that transmits low-powered radio signals and uses machine learning algorithms to analyze their reflections and produce physiological metrics. The device can gather data on patient mobility, gait, breathing, heart rate, sleep stages, sleep apnea, and other metrics without requiring the patient to wear sensors or change their behavior in any way. Novartis and the MIT team explored the potential use of this technology in clinical trials to collect digital biomarkers, both existing and new, and potentially allow continuous, real-time monitoring of patients in their own homes.
As part of the collaboration, Novartis deployed the technology in a Novartis facility, as well as in a life sciences facility with a living lab, sleep monitoring, motion and behavior monitoring. Individuals were studied for multiple days in the lab, and their motion, breathing, sleep, and behavior were measured using the technology and compared against existing standards for such measurements. Comparison to the gold standard shows that the technology has the potential to capture movement and physiological metrics, without being intrusive or requiring changes in people’s behaviors.
“Innovative machine learning and digital solutions, like ours, promise to change how clinical trial patients are conveniently monitored. Our collaboration with Novartis has demonstrated the potential of our touchless continuous monitoring devices, and we are thrilled about continuing to make a difference in clinical research with our cutting edge digital technology,” said Professor Katabi, Director of the MIT Center for Wireless Networks and Mobile Computing,
“This collaboration with Professor Katabi’s team at MIT exemplifies what like-minded academic and industry innovators can achieve in advancing exciting new digital technologies out of the laboratory and onto a path toward possible regulatory acceptance,” said Jay Bradner, President of the Novartis Institutes for BioMedical Research.
Professor Katabi and Novartis are now considering next steps for further examination of this promising technology.
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political and economic conditions; safety, quality or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 105 000 people of more than 140 nationalities work at Novartis around the world. Find out more at http://www.
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.
For Novartis multimedia content, please visit http://www.
For questions about the site or required registration, please contact [email protected]
Novartis Media Relations
E-mail: [email protected]
Novartis Institutes for BioMedical Research
+1 617 710 5447